Herren Drugs & Pharmaceuticals Limited was incorporated as a private
 limited company on November 29, 1984 and was subsequently converted
 to a public limited company on August 29, 1992 for the manufacture of
 bulk drugs.
 
 The company commenced its commercial production in October, 1989 with
 an installed capacity of 72 TPA and has increased its capacity to 252
 TPA in Sept, 1993 and has been involved in the production of
 Ibuprofen, Sulphamethoxazole (SMX), Norfoxacin and Pefloxacin.  
 
 SUBSIDIARY OF THE COMPANY
 
 The Company does not have any subsidiaries.
 
 GROUP PROFILE
 
 HERREN DRUGS & PHARMACEUTICALS LIMITED is the flagship company of the
 Herren Group, founded by Mr.Sarat Gopal.
 
 Besides Herren Drugs a Pharmaceuticals Ltd., Mr.Sarat Gopal has also
 successfully promoted four other Bulk Drug and Intermediate
 manufacturing units, M/s.Dolphin Drugs (P) Ltd., United
 Intermediaries & Chemicals (P) Limited, Dymes Engineers (P) Limited
 and M/s.Dymes Exports Ltd.
 
 The Group owes its success and growth largely to its Promoters for
 their dynamic vision and total dedication.
 
 With a modest turnover of Rs.25.00 lakhs in the year 1989-90 the
 Group has enjoyed a steady growth resulting in a total turnover of
 Rs.25.00 crores for the year ended 31st March 1994.
 
 2002
 
 -N Prasad appointed as MD of Matrix Lab.
 
 -Matrix Lab and Medicorp form a strategic alliance to establish a
 strong presence in the
 Global Active Pharmaceutical Ingredient.
 
 2003
 
 -Matrix Laboratories announces the change in the designation of whole
 time directors:
 1. Mr.M Ravinder as Executive Vice-President.
 2. Mr R Sundara Rajan as Executive Vice-President.
 
 -Matrix Laboratories completes merger of Vorin Labs and Medicorp
 India with it.
 
 -Matrix Lab receives approval from US Food and Drug Administrations
 for fluconazole
 Active Pharmaceutical Ingredient.
 
 -Matrix Lab submits application for drug master files for seven of
 the company produts
 in the US markets.
 
 -Lundbeck withdraws allegations of Forgery made against Matrix
 Laboratories
 
 -Signed agreement with William J Clinton Presidential Foundation for
 the supply of Antiretroviral for the treatment of HIV and AIDs
 patients in certain developing countries.
 
 To issue 22,50,000 equity shares at Rs 1500/- per share aggregating
 to Rs 3375 mn on Preferential basis to Newbridge Capital and other
 investors subject to shareholders approval.
 
 To issue 'No Objection' to New Bridge Capital and other investors to
 enable them approach Foreign Investment Promotion Board (FIPB), to
 obtain their approval for purchase of 18,00,000 equity shares from
 the existing shareholders through a secondary sale and
 
 To convene an Extraordinary Meeting of the members of the company on
 January 29, 2004 for the aforesaid purpose.
 
 2004
 
 -Gets USFDA nod for manufacturing facility located at Jeedimetlla
 
 -Matrix Labs inks pact with India Newbridge Investments
 
 -Matrix Labs appoints Dr. C Satyanarayana as BoD
 
 2005
 
 -Matrix in strategic alliance with MCHEM of China
 
 - Receives US FDA approval for its Active Pharmaceutical Ingredients
 (APIs) manufacturing facility located at Kazipally (Unit-II), near
 Hyderabad. Commissioned in 2004, the facility currently manufactures
 anti-retrovirals (ARVs) for the treatment of HIV / AIDS.